Kite and Arcellx Teams Up to Co-develop and commercialize Late-Stage Clinical Candidate- ddBCMA for the Treatment of Multiple Myeloma
Kite, the cell therapy company, has announced that it has closed global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.
CART-ddBCMA is Arcellx’s T-cell therapy utilizing the company’s novel synthetic binder, the D-Domain. This candidate is currently being investigated in a Phase 2 pivotal trial. Both the partnering companies has planned to jointly advance and commercialize the CART-ddBCMA asset in the U.S., while Kite will commercialize the product outside the U.S.
Kite is also studying cell therapy for other B-cell malignancies and hematologic malignancies, including mantle cell lymphoma (MCL), adult acute lymphoblastic leukemia (ALL), follicular lymphoma (FL) and acute myeloid leukemia (AML).
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases.
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. The company has the largest in-house cell therapy manufacturing network worldwide for process development, vector manufacturing, clinical trial supply and commercial product manufacturing.